AbbVie - ABBV Stock Forecast, Price & News

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of recent analyst reports. SVB Leerink assumed coverage on shares of AbbVie in a research note on Monday, May 23rd. They set an "underperform" rating and a $140.00 price target on the stock. Atlantic Securities reduced their price target on shares of AbbVie from $178.00 to $162.00 and set a "neutral" rating for the company in a research report on Monday, August 1st. Piper Sandler dropped their price objective on AbbVie from $160.00 to $155.00 in a research note on Friday, July 29th. Daiwa Capital Markets downgraded AbbVie from an "outperform" rating to a "neutral" rating and set a $150.00 target price on the stock. in a research report on Friday, May 6th. Finally, Morgan Stanley cut their price target on AbbVie from $191.00 to $188.00 and set an "overweight" rating for the company in a research note on Monday, August 1st. One analyst has rated the stock with a sell rating, six have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $159.63.

AbbVie Trading Up 0.4 %

Shares of AbbVie stock traded up $0.56 during trading hours on Friday, reaching $141.85. The stock had a trading volume of 4,350,050 shares, compared to its average volume of 7,123,692. The company has a current ratio of 0.84, a quick ratio of 0.75 and a debt-to-equity ratio of 4.15. AbbVie has a 1 year low of $105.56 and a 1 year high of $175.91. The firm has a market capitalization of $250.80 billion, a price-to-earnings ratio of 20.09, a P/E/G ratio of 3.97 and a beta of 0.70. The firm has a 50 day simple moving average of $146.44 and a two-hundred day simple moving average of $150.50.

AbbVie (NYSE:ABBV - Get Rating) last announced its quarterly earnings results on Friday, July 29th. The company reported $3.51 earnings per share for the quarter, beating analysts' consensus estimates of $3.42 by $0.09. AbbVie had a net margin of 22.03% and a return on equity of 158.41%. The firm had revenue of $14.58 billion for the quarter, compared to analysts' expectations of $14.64 billion. During the same period in the previous year, the company posted $3.11 earnings per share. AbbVie's revenue was up 4.5% compared to the same quarter last year. As a group, equities research analysts anticipate that AbbVie will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 15th. Stockholders of record on Friday, July 15th were given a $1.41 dividend. This represents a $5.64 annualized dividend and a dividend yield of 3.98%. The ex-dividend date was Thursday, July 14th. AbbVie's payout ratio is 79.89%.

Insider Activity

In related news, Vice Chairman Michael Severino sold 79,801 shares of the business's stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $150.90, for a total transaction of $12,041,970.90. Following the transaction, the insider now directly owns 152,103 shares of the company's stock, valued at approximately $22,952,342.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.08% of the company's stock.